Egfrt/19-28Z/4-1Bbl Car T Cells
Refractory
Memorial Sloan Kettering Cancer CenterCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Cyclophosphamide The Second Hospital of Shandong University | Phase 2 | B |
Pembrolizumab Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Epirubicin Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Isatuximab UNC Lineberger Comprehensive Cancer Center | Phase 2 | CCC |
View all 33 →
Same molecule, other indications
Egfrt/19-28Z/4-1Bbl Car T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →